TY - JOUR
T1 - Prolonged Use of an Automated Insulin Delivery System Improves Sleep in Long-Standing Type 1 Diabetes Complicated by Impaired Awareness of Hypoglycemia
AU - Malone, Susan Kohl
AU - Matus, Austin M.
AU - Flatt, Anneliese J.
AU - Peleckis, Amy J.
AU - Grunin, Laura
AU - Yu, Gary
AU - Jang, Sooyong
AU - Weimer, James
AU - Lee, Insup
AU - Rickels, Michael R.
AU - Goel, Namni
N1 - Funding Information:
The authors thank the study participants with type 1 diabetes for their contribution, Cornelia Dalton-Bakes of the University of Pennsylvania Institute for Diabetes, Obesity & Metabolism Human Metabolism Resource for providing clinical research and regulatory coordination of the parent clinical trial, and Margaret Evangelisti of the University of Pennsylvania Center for Human Phenomic Science for providing actigraphy support. The authors acknowledge support from the Human Metabolism Resource of the Institute for Diabetes, Obesity, & Metabolism at the University of Pennsylvania. They would like to acknowledge Dr Jason Fletcher for providing additional feedback on analyzing the continuous glucose monitoring data and for his input on this manuscript.
Funding Information:
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by NIH grants (R01DK117488 [to N.G.], R01DK091331 (to M.R.R.), K99NR017416 (to S.K.M.), and UL 1TR001878 (University of Pennsylvania Center for Human Phenomic Science). Other support was provided by the National Aeronautics and Space Administration (NASA) (NNX14AN49G and 80NSSC20K0243 [to N.G.]) and from the Pennsylvania Department of Health (SAP 4100079750 [to I.L.]), and from the Charles B. Humpton, Jr. Endowed Fellowship in Diabetes Research (to A.J.F.). Medtronic supplied discounted 670G insulin pumps and continuous glucose monitoring devices for the study through investigator-initiated grant NERP16-015 (to M.R.R.).
Publisher Copyright:
© 2023 Diabetes Technology Society.
PY - 2023
Y1 - 2023
N2 - Background: This study assessed changes in actigraphy-estimated sleep and glycemic outcomes after initiating automated insulin delivery (AID). Methods: Ten adults with long-standing type 1 diabetes and impaired awareness of hypoglycemia (IAH) participated in an 18-month clinical trial assessing an AID intervention on hypoglycemia and counter-regulatory mechanisms. Data from eight participants (median age = 58 years) with concurrent wrist actigraph and continuous glucose monitoring (CGM) data were used in the present analyses. Actigraphs and CGM measured sleep and glycemic control at baseline (one week) and months 3, 6, 9, 12, 15, and 18 (three weeks) following AID initiation. HypoCount software integrated actigraphy with CGM data to separate wake and sleep-associated glycemic measures. Paired sample t-tests and Cohen’s d effect sizes modeled changes and their magnitude in sleep, glycemic control, IAH (Clarke score), hypoglycemia severity (HYPO score), hypoglycemia exposure (CGM), and glycemic variability (lability index [LI]; CGM coefficient-of-variation [CV]) from baseline to 18 months. Results: Sleep improved from baseline to 18 months (shorter sleep latency [P <.05, d = 1.74], later sleep offset [P <.05, d = 0.90], less wake after sleep onset [P <.01, d = 1.43]). Later sleep onset (d = 0.74) and sleep midpoint (d = 0.77) showed medium effect sizes. Sleep improvements were evident from 12 to 15 months after AID initiation and were preceded by improved hypoglycemia awareness (Clarke score [d = 1.18]), reduced hypoglycemia severity (HYPO score [d = 2.13]), reduced sleep-associated hypoglycemia (percent time glucose was < 54 mg/dL, < 60 mg/dL,< 70 mg/dL; d = 0.66-0.81), and reduced glucose variability (LI, d = 0.86; CV, d = 0.62). Conclusion: AID improved sleep initiation and maintenance. Improved awareness of hypoglycemia, reduced hypoglycemia severity, hypoglycemia exposure, and glucose variability preceded sleep improvements. This trial is registered with ClinicalTrials.gov NCT03215914 https://clinicaltrials.gov/ct2/show/NCT03215914.
AB - Background: This study assessed changes in actigraphy-estimated sleep and glycemic outcomes after initiating automated insulin delivery (AID). Methods: Ten adults with long-standing type 1 diabetes and impaired awareness of hypoglycemia (IAH) participated in an 18-month clinical trial assessing an AID intervention on hypoglycemia and counter-regulatory mechanisms. Data from eight participants (median age = 58 years) with concurrent wrist actigraph and continuous glucose monitoring (CGM) data were used in the present analyses. Actigraphs and CGM measured sleep and glycemic control at baseline (one week) and months 3, 6, 9, 12, 15, and 18 (three weeks) following AID initiation. HypoCount software integrated actigraphy with CGM data to separate wake and sleep-associated glycemic measures. Paired sample t-tests and Cohen’s d effect sizes modeled changes and their magnitude in sleep, glycemic control, IAH (Clarke score), hypoglycemia severity (HYPO score), hypoglycemia exposure (CGM), and glycemic variability (lability index [LI]; CGM coefficient-of-variation [CV]) from baseline to 18 months. Results: Sleep improved from baseline to 18 months (shorter sleep latency [P <.05, d = 1.74], later sleep offset [P <.05, d = 0.90], less wake after sleep onset [P <.01, d = 1.43]). Later sleep onset (d = 0.74) and sleep midpoint (d = 0.77) showed medium effect sizes. Sleep improvements were evident from 12 to 15 months after AID initiation and were preceded by improved hypoglycemia awareness (Clarke score [d = 1.18]), reduced hypoglycemia severity (HYPO score [d = 2.13]), reduced sleep-associated hypoglycemia (percent time glucose was < 54 mg/dL, < 60 mg/dL,< 70 mg/dL; d = 0.66-0.81), and reduced glucose variability (LI, d = 0.86; CV, d = 0.62). Conclusion: AID improved sleep initiation and maintenance. Improved awareness of hypoglycemia, reduced hypoglycemia severity, hypoglycemia exposure, and glucose variability preceded sleep improvements. This trial is registered with ClinicalTrials.gov NCT03215914 https://clinicaltrials.gov/ct2/show/NCT03215914.
KW - circadian
KW - diabetes therapeutic technologies
KW - hypoglycemia
KW - insulin delivery
KW - sleep
KW - type 1 diabetes
UR - http://www.scopus.com/inward/record.url?scp=85165300813&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85165300813&partnerID=8YFLogxK
U2 - 10.1177/19322968231182406
DO - 10.1177/19322968231182406
M3 - Article
C2 - 37449426
AN - SCOPUS:85165300813
SN - 1932-2968
JO - Journal of diabetes science and technology
JF - Journal of diabetes science and technology
ER -